MicroRNAs as Novel Biomarkers in Cardiovascular Medicine

Vogel, Britta; Katus, Hugo A.; Meder, Benjamin

doi:10.1002/9783527672165.ch02

Nucleic Acids as Molecular Diagnostics 2014

DOI: 10.1002/9783527672165.ch02

|View full text |Cite

MicroRNAs as Novel Biomarkers in Cardiovascular Medicine

Britta Vogel

Hugo A. Katus

Benjamin Meder

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2019

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Editorial focus: entering into the non-coding RNA era

Bartoszewski

Sikorski

2018

Cell Mol Biol Lett

View full text Add to dashboard Cite

Recent developments in high-throughput genotyping technologies have revealed the existence of several new classes of RNA that do not encode proteins but serve other cellular roles. To date, these non-coding RNAs (ncRNAs) have been shown to modulate both gene expression and genome remodeling, thus contributing to the control of both normal and disease-related cellular processes. The attraction of this research topic can be seen in the increasing number of submissions on ncRNAs to molecular biology journals, including Cellular Molecular Biology Letters (CMBL). As researchers attempt to deepen the understanding of the role of ncRNAs in cell biology, it is worth discussing the broader importance of this research.

show abstract

Editorial focus: entering into the non-coding RNA era

Bartoszewski

Sikorski

2018

Cell Mol Biol Lett

View full text Add to dashboard Cite

show abstract

Editorial focus: understanding off-target effects as the key to successful RNAi therapy

Bartoszewski

Sikorski

2019

Cell Mol Biol Lett

View full text Add to dashboard Cite

With the first RNA interference (RNAi) drug (ONPATTRO (patisiran)) on the market, we witness the RNAi therapy field reaching a critical turning point, when further improvements in drug candidate design and delivery pipelines should enable fast delivery of novel life changing treatments to patients. Nevertheless, ignoring parallel development of RNAi dedicated in vitro pharmacological profiling aiming to identify undesirable off-target activity may slow down or halt progress in the RNAi field. Since academic research is currently fueling the RNAi development pipeline with new therapeutic options, the objective of this article is to briefly summarize the basics of RNAi therapy, as well as to discuss how to translate basic research into better understanding of related drug candidate safety profiles early in the process.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

MicroRNAs as Novel Biomarkers in Cardiovascular Medicine

Cited by 2 publications

References 47 publications

Editorial focus: entering into the non-coding RNA era

Editorial focus: entering into the non-coding RNA era

Editorial focus: understanding off-target effects as the key to successful RNAi therapy

Contact Info

Product

Resources

About